2.55
0.39%
+0.010
Psychemedics Corp. stock is currently priced at $2.55, with a 24-hour trading volume of 648.
It has seen a +0.39% increased in the last 24 hours and a -15.00% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.57 pivot point. If it approaches the $2.51 support level, significant changes may occur.
Previous Close:
$2.54
Open:
$2.55
24h Volume:
648
Market Cap:
$14.80M
Revenue:
$22.10M
Net Income/Loss:
$-4.15M
P/E Ratio:
-7.4758
EPS:
-0.3411
Net Cash Flow:
$-1.64M
1W Performance:
-0.78%
1M Performance:
-15.00%
6M Performance:
+8.05%
1Y Performance:
-52.78%
Psychemedics Corp. Stock (PMD) Company Profile
Name
Psychemedics Corp.
Sector
Industry
Phone
978 206 8220
Address
289 Great Road, Suite 200, Acton, MA
Psychemedics Corp. Stock (PMD) Latest News
Psychemedics Corporation Reports 2023 Financial Results
GlobeNewswire Inc.
Psychemedics Recognized as a Top 10 Employee Health Testing Services Provider
GlobeNewswire Inc.
Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas
GlobeNewswire Inc.
Psychemedics Corporation Reports Third Quarter 2023 Financial Results
GlobeNewswire Inc.
Psychemedics Corp. Stock (PMD) Financials Data
Psychemedics Corp. (PMD) Revenue 2024
PMD reported a revenue (TTM) of $22.10 million for the quarter ending December 31, 2023, a -12.45% decline year-over-year.
Psychemedics Corp. (PMD) Net Income 2024
PMD net income (TTM) was -$4.15 million for the quarter ending December 31, 2023, a -283.21% decrease year-over-year.
Psychemedics Corp. (PMD) Cash Flow 2024
PMD recorded a free cash flow (TTM) of -$1.64 million for the quarter ending December 31, 2023, a -134.81% decrease year-over-year.
Psychemedics Corp. (PMD) Earnings per Share 2024
PMD earnings per share (TTM) was -$0.72 for the quarter ending December 31, 2023, a -276.77% decline year-over-year.
About Psychemedics Corp.
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.
Cap:
|
Volume (24h):